echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > China's State Drug Administration has approved a Phase I/II clinical trial of ATG-016 (Eltanexor) to treat high-risk bone marrow growth syndrome

    China's State Drug Administration has approved a Phase I/II clinical trial of ATG-016 (Eltanexor) to treat high-risk bone marrow growth syndrome

    • Last Update: 2020-12-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bone marrow growth abnormal syndrome (MDS) includes a range of blood system diseases characterized by chronic blood cell reduction (anemia, nemetic granulocyte reduction, and plate reduction) accompanied by abnormal cell maturation.
    , MDS patients are at risk of developing symptomatic anemia, infection, bleeding, and developing acute myeloid leukemia (AML, often difficult to treat).
    Antegen is a leading biopharmaceutical company dedicated to developing best-in-class therapies for hematology and oncology.
    recently, China's State Drug Administration (NMPA) has approved a clinical trial of ATG-016 (eltanexor) for the treatment of high-risk bone marrow growth syndrome (MDS).
    this trial is a phase I/II single-arm open-label clinical study designed to assess the pharmacodynamics, safety and ability of ATG-016 (eltanexor).
    total survival (OS) in patients with resoicative high-risk MDS was only 4-6 months, and follow-up treatment options were limited.
    Preclinical studies have shown that nuclear transport selective inhibitors (SINE) can block the nuclear output of many tumor suppressor proteins (e.g. p53, IkB, p21), resulting in their accumulation and resuspension in the nucleus, thus playing an anti-tumor role.
    ATG-016 is a member of the latest generation of SINE compounds.
    , the ATG-016 has blood-brain barrier permeability compared to the first generation of SINE, which shows initial anti-cancer activity in patients with high-risk MDS.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.